



Robert Greene Sterne  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Horner  
Robert C. Millonig  
Donald J. Featherstone  
Timothy J. Shea, Jr  
Michael V. Messinger  
Judith U. Kim

Patrick E. Garrett  
Jeffrey T. Helvey  
Heidi L. Kraus  
Eldora L. Ellison  
Thomas C. Fiala  
Donald R. Banowitz  
Peter A. Jackman  
Jeffrey S. Weaver  
Brian J. Del Buono  
Vincent L. Capuano  
Virgil Lee Beaston  
Theodore A. Wood  
Elizabeth J. Haanes  
Joseph S. Ostroff  
Frank R. Cottingham  
Rae Lynn P. Guest  
Daniel A. Klein  
Jason D. Eisenberg

Michael D. Specht  
Tracy L. Muller  
Jon E. Wright  
LuAnne M. DeSantis  
Ann E. Summerfield  
Helene C. Carlson  
Cynthia M. Bouchez  
Timothy A. Doyle  
Gaby L. Longworth  
Lori A. Gordon  
Ted J. Ebersole  
Laura A. Vogel  
Bryan S. Wade  
Bashir M.S. Ali  
Shannon A. Carroll  
Matthew E. Kelley  
Michelle K. Holoubek  
Marsha A. Rose

W. Blake Coblenz  
James J. Pohl\*  
John T. Haran\*  
Mark W. Rygiel  
  
Registered Patent Agents\*  
Karen R. Markowicz  
Matthew J. Dowd  
Katrina Yujian Pei Quach  
Bryan L. Skelton  
Robert A. Schwartzman  
Teresa A. Colella  
Victoria S. Rutherford  
Simon J. Elliott  
Julie A. Heider  
Mita Mukherjee  
Scott M. Woodhouse  
Christopher J. Walsh

Liliana Di Nola-Baron  
Peter A. Socarras  
Jeffrey Mills  
Danielle L. Letting  
Lori Brandes

Of Counsel  
Edward J. Kessler  
Kenneth C. Bass III  
Marvin C. Guthrie

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Practice Limited to  
Federal Agencies

February 23, 2006

WRITER'S DIRECT NUMBER:  
(202) 772-8610

INTERNET ADDRESS:  
SELLIOTT@SKGF.COM

**Attn: Mail Stop Missing Parts**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Re: U.S. Utility Patent Application  
Application No. 09/809,060; Filed: March 16, 2001  
For: **A Method for Generating Immunogens that Elicit Neutralizing  
Antibodies Against Fusion-Active Regions of HIV Envelope Proteins**  
Inventors: Carl T. WILD *et al.*  
Our Ref: 1900.0260001/JMC/SJE

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Request for Corrected Official Filing Receipt;
2. Copy of Official Filing Receipt with correction noted in red;
3. Copy of Postcard with PTO stamp, dated September 16, 2003;
4. Copy of Power of Attorney from Assignee; filed September 16, 2003; and
5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
February 23, 2006  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Simon J. Elliott  
Agent for Applicants  
Registration No. 54,083

JMC/SJE:cpn  
Enclosures  
499257\_1.DOC



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Carl T. WILD *et al.*

Appl. No.: 09/809,060

Filed: March 16, 2001

For: **A Method for Generating Immunogens  
that Elicit Neutralizing Antibodies  
Against Fusion-Active Regions of HIV  
Envelope Proteins**

Confirmation No.: 4671

Art Unit: 1648

Examiner: Lucas, Zachariah

Atty. Docket: 1900.0260001/JMC/SJE

**Request for Corrected Official Filing Receipt**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

*Mail Stop Missing Parts*

Sir:


Applicants hereby request that a corrected Official Filing Receipt be issued and sent to the undersigned representative. Specifically, the following correction to the Official Filing Receipt is requested: "**Kristin Vidovich-41448**" to "**The patent practioners associated with Customer Number 28393**". In support of the above request, a marked-up copy of the instant Official Filing Receipt is enclosed to show the corrections. A copy of the Power of Attorney to the patent practioners associated with Customer Number 28393, filed September 16, 2003, is enclosed. It is requested that a corrected Official Filing Receipt be issued, and sent to the undersigned at the earliest possible time.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Simon J. Elliott  
Agent for Applicants  
Registration No. 54,083

Date: February 23, 2006  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

**UNITED STATES PATENT AND TRADEMARK OFFICE**

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
09/809,060	03/16/2001	1648	525	1900.0260001/JMC/CML	7	30	5

**CONFIRMATION NO. 4671**

26111

STERNE, KESSLER, GOLDSTEIN & FOX PLLC  
1100 NEW YORK AVENUE, N.W.  
WASHINGTON, DC 20005




Date Mailed: 06/23/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Carl T. Wild, Gaithersburg, MD;  
Graham P. Allaway, Darnestown, MD;

**Power of Attorney:**

~~Resubmitted 41446~~  
The Patent practitioners associated with Customer Number 28393

**Domestic Priority data as claimed by applicant**

This appln claims benefit of 60/189,981 03/17/2000

**Foreign Applications**

If Required, Foreign Filing License Granted: 05/24/2001

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US09/809,060**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

**\*\* SMALL ENTITY \*\***

**Title**

Method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of HIV envelope proteins

**Preliminary Class**

424

## **PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

---

### **LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.


This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject

matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



**Due Date:** None

**Applicants:** Wild et al.

**Art Unit:** 1646

**Application No.:** 09/809,060

**Examiner:** To Be Assigned

**Filed:** March 16, 2001

**Docket:** 1900.0260001

**Atty:** JMC

**For: A Method for Generating Immunogens that Elicit Neutralizing Antibodies  
Against Fusion-Active Regions**


When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. SKGF Cover Letter;
2. Fee Transmittal Form (PTO/SB/17);
3. Recordation Form Cover Sheet (Form PTO-1595);
4. Assignment to Panacos Pharmaceuticals, official recordation and return of which are respectfully requested;
5. Certificate Under C.F.R. §3.73(b);
6. Power of Attorney from Assignee;
7. PTO-2038 Credit Card Payment Form for \$40.00 to cover: \$40.00 for Recordation of Assignment and
8. One (1) return postcard.



**Please Date Stamp And Return To Our Courier**

SKGF\_DC1:179041.1



## POWER OF ATTORNEY FROM ASSIGNEE

Panacos Pharmaceuticals, Inc., a corporation of Maryland, having a principal place of business at 209 Perry Parkway, Gaithersburg, MD 20877, is assignee of the entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), by reason of an Assignment to the Assignee executed on (1) (2) of an invention known as A Method for Generating Immunogens that Elicit Neutralizing Antibodies Against Fusion-Active Regions of HIV Envelope Proteins (Attorney Docket No. 1900.0260001/JMC/CML), which is disclosed and claimed in a patent application of the same title by the inventors Carl T. Wild and Graham P. Allaway (said application filed on March 16, 2001 at the U.S. Patent and Trademark Office, having Application Number 09/809,060).

The Assignee hereby appoint the U.S. attorneys associated with **CUSTOMER NUMBER 28393** to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith, such attorneys currently being: Robert Greene Sterne, Esq., Reg. No. 28,912; Edward J. Kessler, Esq., Reg. No. 25,688; Jorge A. Goldstein, Esq., Reg. No. 29,021; David K.S. Cornwell, Esq., Reg. No. 31,944; Robert W. Esmond, Esq., Reg. No. 32,893; Tracy-Gene G. Durkin, Esq., Reg. No. 32,831; Michele A. Cimbala, Esq., Reg. No. 33,851; Michael B. Ray, Esq., Reg. No. 33,997; Robert E. Sokohl, Esq., Reg. No. 36,013; Eric K. Steffe, Esq., Reg. No. 36,688; Michael Q. Lee, Esq., Reg. No. 35,239; Steven R. Ludwig, Esq., Reg. No. 36,203; John M. Covert, Esq., Reg. No. 38,759; Linda E. Alcorn, Esq., Reg. No. 39,588; Lawrence B. Bugaisky, Esq., Reg. No. 35,086; Donald J. Featherstone, Esq., Reg. No. 33,876; Robert C. Millonig, Esq., Reg. No. 34,395; Michael V. Messinger, Esq., Reg. No. 37,575; Judith U. Kim, Esq., Reg. No. 40,679; Timothy J. Shea, Jr., Esq., Reg. No. 41,306; and Patrick E. Garrett, Esq., Reg. No. 39,987. The Assignee hereby grants said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
U.S.A.

Direct phone calls to 202-371-2600.

FOR: Panacos Pharmaceuticals, Inc.

SIGNATURE: \_\_\_\_\_

BY: Graham P. Allaway

TITLE: President

DATE: 4/2/03

SKGF\_DC1:108699.1